A veterinary sedative used to tranquillise elephants is now showing up in the illegal drug supply across New York State. Authorities warn the medetomidine overdose crisis is more dangerous than anything they have seen in recent years. Dealers quietly mix this powerful animal sedative into opioid supplies without users’ knowledge, triggering a surge in deaths and life-threatening withdrawal episodes.
What Is Medetomidine and Why Is It Fuelling Overdose Deaths?
Most people have never heard of medetomidine. Veterinarians use it to sedate large animals, including elephants. Over the past two years, it has entered the illicit drug market at a pace that alarms toxicologists, paramedics, and prosecutors alike.
Assistant District Attorney Matthew Gamberg is deputy chief of the Narcotics-Investigations Bureau in Staten Island. He told the Staten Island Fentanyl and Overdose Task Force in March 2025 that medetomidine is 200 to 300 times more potent than xylazine. Xylazine is another veterinary drug previously linked to overdose deaths and disability.
“Xylazine is still prevalent in the drug supply, but its presence is definitely on a downward trend,” Gamberg said. “It is being replaced with medetomidine, which, for all intents and purposes, is worse.”
Dealers add the drug to fentanyl to extend its effects. Fentanyl wears off in roughly half the time heroin does. So dealers blend in medetomidine and xylazine to prolong the high. That combination carries lethal consequences for unsuspecting users.
How Fast Is the Medetomidine Overdose Crisis Spreading?
The numbers tell a troubling story. New York State Drug Checking Programmes first spotted medetomidine in a sample in May 2024. Just four months later, it turned up in over 23% of opioid samples tested.
By October 2025, that figure reached 37% of all opioid samples. During the same period, xylazine appeared in 40% of opioid samples. Two potent veterinary sedatives now circulate simultaneously in the street supply.
The New York State Department of Health issued a public health alert in December, citing life-threatening side effects and the rapid spread of medetomidine across the state’s drug market.
It Makes Naloxone Less Effective
One of the most frightening parts of the medetomidine overdose crisis is how it undermines naloxone, the most widely used overdose reversal tool available (commonly known as Narcan).
Medetomidine is not an opioid. Naloxone does not fully reverse its effects. Emergency responders may administer naloxone and revive a patient from opioid-related respiratory depression. Yet the person can remain deeply sedated because the medetomidine component stays active.
This gap complicates emergency care significantly. Communities relying on naloxone as a first-line response now work with an incomplete tool. In cases involving veterinary drug overdose deaths linked to medetomidine, that gap can cost lives.
Withdrawal from Medetomidine Can Kill
The dangers do not end with the overdose itself. The New York City Department of Health and Mental Hygiene warns that medetomidine withdrawal can require intensive medical care and hospitalisation.
Emergency room visits for medetomidine withdrawal rose sharply last year. Opioid withdrawal is deeply unpleasant but rarely fatal for otherwise healthy adults. Medetomidine withdrawal is different. It disrupts the cardiovascular system and can cause blood pressure to drop, heart rate to slow, and breathing to suppress.
Health officials urge anyone withdrawing from drugs that may contain medetomidine to seek immediate medical attention. Trying to manage those symptoms at home puts lives at serious risk.
Fake Anti-Anxiety Pills Add to the Medetomidine Overdose Crisis
Medetomidine is not the only new danger circulating in the illicit market. In March 2026, the US Drug Enforcement Administration (DEA) issued a nationwide alert about bromazolam. This synthetic benzodiazepine now appears in counterfeit prescription pills designed to look like anti-anxiety medications such as alprazolam (Xanax).
The DEA elevated bromazolam to the top tier of the controlled substances schedule on an emergency basis through March 2028. Trafficking has increased and the drug carries no accepted medical use and a high potential for abuse.
Manufacturers frequently mix bromazolam with fentanyl. Counterfeit pills are notoriously difficult to tell apart from legitimate ones by sight alone. The DEA has repeatedly warned that fake prescription pills can contain fatal doses of fentanyl.
Bromazolam causes slurred speech, loss of bodily coordination, altered mental state, and respiratory depression.
Cocaine Rises as Fentanyl Trends Down Slightly
There is a partial bright spot in the data. Fentanyl remains the leading driver of overdose deaths, but its potency and prevalence show some decline on Staten Island. Gamberg says law enforcement officers in the borough now recover less fentanyl and more cocaine.
Cocaine’s rise carries its own risks. It rarely kills on its own, but it frequently appears alongside fentanyl in fatal overdose toxicology reports. The United Nations World Drug Report 2025 found that global cocaine production reached an all-time high, with significant increases in seizures, users, and cocaine-related deaths across many countries.
Nearly every drug law enforcement recovers on the island, except cocaine, tests positive for multiple substances. Heroin almost always combines with fentanyl, medetomidine, xylazine, and lidocaine. A single sample can contain over 20 different substances. That complexity makes overdose reversal far harder.
Overdose Deaths Are Falling, but the Veterinary Drug Overdose Deaths Toll Remains Too High
Staten Island has made real progress. Overdose deaths in the borough fell by nearly 50% in 2024. Preliminary figures suggest that downward trend continued through 2025 and into 2026.
But District Attorney Michael E. McMahon was clear: the numbers remain unacceptably high. He hosted the March task force meeting and cautioned that the spread of medetomidine, bromazolam, and increasingly complex drug combinations demands that response strategies keep evolving.
Communities, healthcare providers, and policymakers must stay current on the medetomidine overdose crisis. Early detection, stronger withdrawal treatment protocols, and broader public awareness are not optional. For anyone struggling with substance use, or for those who love someone who is, knowing what is in the supply chain today can be a matter of life and death.
(Source: WRD News)